Showing results (831-840 of 8,120) with videos related to

Sort By:
Pageof 812
Haematologica|August 1, 2020
MYB bi-allelic targeting abrogates primitive clonogenic progenitors while the emergence of primitive blood cells is not affectedZahir Shah, Elena S Filonenko, Vasily Ramensky, et al.
Haematologica|April 22, 2021
Targeting the tumor microenvironment in chronic lymphocytic leukemiaRebecka Svanberg, Sine Janum, Piers E M Patten, et al.
Haematologica|April 15, 2021
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndromeMahesh Swaminathan, Hagop M Kantarjian, Mark Levis, et al.
Haematologica|April 15, 2021
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemiaDan Cojocari, Brianna N Smith, Julie J Purkal, et al.
Haematologica|March 15, 2015
Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flowFrauke Swieringa, Marijke J E Kuijpers, Moniek M E Lamers, et al.
Haematologica|March 15, 2015
BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2Jie Ding, Wilhelm G Dirks, Stefan Ehrentraut, et al.
Haematologica|September 10, 2002
Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical studyMichele Cavo, Monica Benni, Sonia Ronconi, et al.
Haematologica|September 10, 2002
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patientsFrancesca R Mauro, Robin Foa, Giovanna Meloni, et al.
Haematologica|September 10, 2002
Defective expression of GPIb/IX/V complex in platelets from patients with May-Hegglin anomaly and Sebastian syndromeMichele Di Pumpo, Patrizia Noris, Alessandro Pecci, et al.
Haematologica|September 10, 2002
Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulinFrancesco Graziani, Maria Teresa Van Lint, Alida Dominietto, et al.
Pageof 812